查看更多
密码过期或已经不安全,请修改密码
修改密码
壹生身份认证协议书
同意
拒绝
同意
拒绝
同意
不同意并跳过
《癌症生物学与医学》
Cancer Biology & Medicine
为中国抗癌协会和天津医科大学肿瘤医院共同主办的OA月刊,由国家恶性肿瘤临床医学研究中心主任、天津市肿瘤研究所所长郝希山院士创办并担任主编。重点关注肿瘤转化研究,肿瘤早诊早治,肿瘤精准医学等领域最新前沿,旨在搭建高质量国际化学术交流平台,入选中国科技期刊卓越行动计划项目。期刊现已被SCIE(IF=8.4)、MEDLINE以及PubMed/PubMed Central等国内外主要数据库收录。读者可通过此链接浏览全文http://www.ncbi.nlm.nih.gov/pmc/journals/2000/
人工智能赋能乳腺癌个体化治疗
乳腺癌是全球女性发病率最高的恶性肿瘤,持续给全球公共卫生带来严峻挑战。近年来,精准医学、靶向治疗、免疫治疗及转化研究的快速发展,深刻改变了乳腺癌的诊疗格局。特别是人工智能的崛起,正于海量医疗数据与精准临床决策间架设桥梁,为乳腺癌的早期筛查、精准诊断、个体化治疗及预后评估,开辟出前所未有的崭新领域。然而,医疗资源分布不均、疾病特征的地区差异以及如何更有效地将技术创新转化为临床实践,仍是实现全球乳腺癌公平、高质量诊疗的关键障碍。
值此背景下,Cancer Biology & Medicine特邀中国人民解放军总医院江泽飞教授策划“人工智能赋能乳腺癌个体化治疗”专刊,旨在汇聚国内外顶尖专家智慧,系统呈现乳腺癌诊疗的新进展、新思考与新突破。本专刊聚焦乳腺癌精准诊疗前沿,涵盖人工智能在影像诊断与病理诊断中的创新应用、新型治疗手段的精准策略以及基于多组学分析的转化研究探索等方向,特别关注人工智能在诊断、治疗决策及预后评估中的赋能作用,为推进乳腺癌精准诊疗的深化提供前沿证据与学术洞见。
GUEST EDITOR
江泽飞 教授
中国人民解放军总医院
解放军总医院肿瘤医学部副主任
中国临床肿瘤学会(CSCO)候任理事长
北京医学会乳腺疾病学分会主任委员
St.Gallen国际乳腺癌专家共识主席团成员
TABLE OF CONTENTS
Harnessing Artificial Intelligence for Personalized Breast Cancer
Preface
Artificial intelligence empowering precision diagnosis and treatment of breast cancer: advancing global clinical practice with regional insights
Zefei Jiang
Editorial
Balancing global standards and regional nuances in breast cancer care: the role of guidelines, clinical research, precision medicine, and artificial intelligence in advancing quality of care for patients worldwide
Michael Gnant
Precision immunotherapy for breast cancer: from biomarkers to clinical practice
Jie Mei, Kai Yang, Xinkang Zhang, Xiang Huang and Yongmei Yin
Advances in TROP2-targeted antibody-drug conjugates for breast cancer therapy: into the new era
Kuikui Jiang and Shusen Wang
Perspective
Protocol and statistical designs in classic clinical research—toripalimab series trial analysis
Yingjian He, Li Bian and Zefei Jiang
Reviews
The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer
Yilin Chen, Ye Qin, Man Yang, Wei Li, Minyi Cheng, Yuhong Huang, Teng Zhu and Kun Wang
Artificial intelligence in breast cancer: applications and advancements
Jianbin Li and Zefei Jiang
Original Articles
Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer
Yaxin Zhao, Han Wang, Ying Wang, Yizhou Jiang, Xin Hu and Zhiming Shao
Metabolic engineering of SLC38A2 reprograms glutamine utilization and enhances CAR-macrophage antitumor function in solid tumors
Mingzhu Liu, Qingxi Chen, Luoling Zhang, Yunxuan Zhou, Ning Wen, Jin Jin, Junchao Cai, Shicheng Su, Jiang Li and Qiyi Zhao
Virtual histology imaging of lymph nodes via dynamic full-field optical coherence tomography and deep learning to differentiate metastasis
Shuwei Zhang, Houpu Yang, Yiyin Zhang, Xiaoxian Li, Jin Zhao, Yuanyuan Zhang, Ping Xue, Hua Kang, Hongchuan Jiang, Wenhui Ren and Shu Wang
Multimodal artificial intelligence predicts PIK3CA mutation in breast cancer from digital pathology and clinical data: a multicenter study
Jiaxian Miao, Qi Liu, Jianing Zhao, Shishun Fan, Shenwen Wang, Feng Ye, Si Wu, Jinze Li, Huirui Zhang, Meng Zhang, Hong Bu, Xiao Han, Lianghong Teng and Yueping Liu
封面故事
Cover Story
宣纸黄的底色晕开医学探索的千年文脉,机械臂与人类双手在试管DNA的星河中相遇,半片药片在掌心完成了智能与生命的握手。这幅画面映照出乳腺癌诊疗领域的深刻变革:人工智能正从辅助工具成长为对抗肿瘤的核心伙伴。从基因组数据挖掘、分子分型精准识别及靶向治疗研发,人工智能正在重塑从科学发现到临床实践的全程。人类的临床经验为人工智能提供高质量数据燃料,算法则将复杂信息转化为精准洞见。人机协同,让乳腺癌诊疗从经验驱动迈向数据驱动,为患者带来更长久、更有质量的生命曙光。
来源:Cancer Biology Medicine
查看更多